News Digest / Ticker: RXRX

Ticker: RXRX

07:04am, Tuesday, Aug 05, 2025

Recursion Pharmaceuticals Reports Major Q2 2025 Losses Despite Revenue Growth and Strategic Advances

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) - Q2 2025 Financial Summary Key Highlights: Net Loss: $171.9 million for Q2 2025, up from $97.5 million in Q2 2024, showing a 76% increase. Operating Revenue: $19.1 million, a 33% increase compared to $14.4 million in Q2 2024. Operating Costs: Incre...

07:03am, Monday, May 05, 2025

Recursion Pharmaceuticals Reports Q1 2025 Earnings: Revenue Up, Net Loss Widens Amid Rising Expenses

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) has reported its quarterly earnings for the first quarter of 2025, reflecting ongoing challenges and notable changes within the company. Financial Highlights: Total Revenue: $14.745 million, up from $13.794 million in Q1 2024 (7% increase). Operatin...